【摘要】 目的探讨切除修复交叉互补基因1(ERCC1)在乳腺癌组织中的表达与临床病理特征及预后的关系。方法应用实时荧光定量PCR技术检测363例乳腺癌组织中ERCC1 mRNA的相对表达水平,分析其表达与乳腺癌临床病理特征及预后之间的关系。结果 363例乳腺癌组织标本中ERCC1 mRNA的中位表达水平为1.02×10-2,其中ERCC1 mRNA高表达者181例,ERCC1 mRNA低表达者182例。ERCC1 mRNA表达水平与ER、PR表达有关(P<0.05),而与患者的年龄、肿瘤大小、腋窝淋巴结转移、病理类型、组织学分级、HER-2的表达均无关(P>0.05)。ERCC1 mRNA高表达与低表达者的中位无病生存期(DFS)均为未达到,差异无统计学意义(P>0.05)。ERCC1 mRNA高表达者的中位无进展生存期(PFS)为34.0个月(95%CI:32.004~35.996个月),低表达者的中位PFS为未达到,两组差异有统计学意义(P=0.017)。结论乳腺癌中ERCC1 mRNA的表达可能与患者的雌激素代谢相关,检测ERCC1 mRNA的表达水平可能有助于判断乳腺癌患者的生存和预后。更多还原

【Abstract】 Objective To investigate the expression of excision repair cross complement group 1( ERCC1) in breast carcinoma and their relationship between the expression and clinicopathological characteristics and prognosis. Methods Real-time quantitative PCR was used to determine the mRNA expression of ERCC1 in 363 breast carcinoma patients. The relationship between the expression and clinicopathological characteristics and prognosis were analyzed. Results The median expression level of ERCC1 mRNA was 1. 02 × 10- 2in 363 breast carcinoma tissues,with 181 patients in high level group,and 182 in low level group. Expression of ERCC1 mRNA was associated with expressions of ER,PR( P < 0. 05),but not with patients’ age,tumor size,axillary lymph node metastasis, pathological type,histological grade,HER-2( P > 0. 05). The median disease-free survival in patients with high ERCC1 mRNA expression and low ERCC1 mRNA expression were both not reached with no statistical difference( P > 0. 05). The median progress-free survival( PFS) was 34. 0 months( 95% CI: 32. 004-35. 996) in patients with high ERCC1 mRNA expression. The median PFS in patients with low ERCC1 mRNA expression was not reached. There was statistical difference( P = 0. 017). Conclusion The expression of ERCC1 mRNA in breast cancer may be closely related to estrogen metabolism of patients. Detection of ERCC1 mRNA expression may help to predict the survival and prognosis of breast cancer patients.更多还原